A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
every two cycles
James A Stewart, M.D.
University of Wisconsin PPC Comprehensive Cancer Center
United States: Institutional Review Board
|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center||Madison, Wisconsin 53792-6164|